What is the recommended management for acute respiratory distress syndrome (ARDS)?

ARDS Management

Core Mechanical Ventilation Strategy

Implement lung-protective ventilation immediately with tidal volumes of 6 mL/kg predicted body weight and plateau pressure ≤30 cmH₂O—this is the single most critical intervention proven to reduce mortality across all ARDS severities. 1

• Calculate predicted body weight using gender-specific formulas: males = 50 + 2.3 × (height in inches − 60); females = 45.5 + 2.3 × (height in inches − 60) 2
• Maintain plateau pressure ≤30 cmH₂O (ideally <28 cmH₂O) by performing end-inspiratory pauses of 0.3–0.5 seconds to confirm lung-protective ventilation 1, 2
• Target PaO₂ of 70–90 mmHg or SpO₂ of 92–97% to avoid oxygen toxicity while ensuring adequate tissue oxygenation 2
• Monitor and minimize driving pressure (plateau pressure minus PEEP), as this correlates directly with mortality 2

PEEP Strategy by Severity

• Moderate-to-severe ARDS: Use higher PEEP (typically 10–15 cmH₂O) over lower PEEP, titrating to oxygenation response, maximal respiratory system compliance, or highest safe plateau pressure 1
• Mild ARDS: Use lower PEEP strategies (5–10 cmH₂O), as higher PEEP shows no benefit and potential harm in this population 3
• Avoid prolonged recruitment maneuvers (e.g., 40 cmH₂O for 40 seconds), as randomized trials show no mortality benefit and risk hemodynamic compromise 2

Severity-Based Adjunctive Therapies

Severe ARDS (PaO₂/FiO₂ <150 mmHg)

Initiate prone positioning for ≥12 hours daily (preferably 16–20 hours) immediately when PaO₂/FiO₂ falls below 150 mmHg—this reduces 28-day mortality from 32% to 16%. 1, 2

• Continue daily prone positioning until PaO₂/FiO₂ exceeds 150 mmHg for at least 48 hours 2
• Contraindications include open abdominal wounds, unstable pelvic fractures, spinal instability, and unmonitored brain injury 2

Administer continuous cisatracurium infusion for 48 hours in early severe ARDS (PaO₂/FiO₂ <150 mmHg) to eliminate patient-ventilator dyssynchrony and reduce mortality. 1, 2

• Discontinue after 48 hours (or sooner if rapid improvement) to limit ICU-acquired weakness 2
• Use only when dyssynchrony persists despite ventilator adjustments 2

Consider early low-dose corticosteroids in moderate-to-severe ARDS, as this may reduce mortality when initiated early in the disease course. 2

• Avoid high-dose or pulse-dose steroids, which do not improve survival and increase long-term muscle weakness 2

Mild ARDS (PaO₂/FiO₂ 200–300 mmHg)

• Do not routinely use prone positioning or neuromuscular blockade, as these interventions are indicated only for severe ARDS 3
• Maintain lung-protective ventilation with lower PEEP strategies (5–10 cmH₂O) 3

Fluid Management

Implement conservative fluid strategy targeting net negative fluid balance (approximately 500–1000 mL/day) once hemodynamic stability is achieved, as this improves oxygenation and shortens ventilator days without increasing organ failure. 1, 2

Rescue Therapies for Refractory Severe ARDS

Consider venovenous ECMO after optimizing lung-protective ventilation, prone positioning, and neuromuscular blockade if PaO₂/FiO₂ remains <70 mmHg for ≥3 hours or <100 mmHg for ≥6 hours. 2

• Transfer patients meeting ECMO criteria to specialized centers, as this is associated with reduced mortality 2
• ECMO probably decreases mortality and increases ventilator-free days in severe ARDS 2

Do not use high-frequency oscillatory ventilation routinely—randomized trials show no mortality benefit and trend toward harm. 1, 2

• Reserve HFOV only as last-resort rescue in the most severe hypoxemia (PaO₂/FiO₂ <70 mmHg) 2

Interventions NOT Recommended

• β-2 agonists: Do not use for ARDS treatment without bronchospasm 1
• Pulmonary artery catheter: Do not use routinely 1
• Inhaled nitric oxide: May improve oxygenation transiently but has no proven survival advantage; stop if no rapid response 2

Monitoring and Supportive Care

• Continuously assess PaO₂/FiO₂ ratio to detect progression between ARDS severity categories 2
• Perform serial plateau pressure measurements with end-inspiratory pauses to confirm lung-protective ventilation 2
• Monitor for right ventricular dysfunction with echocardiography, as this occurs in 20–25% of ARDS patients 2
• Elevate head of bed ≥30 degrees to reduce aspiration risk and prevent ventilator-associated pneumonia 1
• Provide stress ulcer prophylaxis and venous thromboembolism prophylaxis 2
• Initiate early enteral nutrition with antioxidant-containing formulations 2

Weaning Protocol

• Perform daily spontaneous breathing trials when patients are: arousable, hemodynamically stable without vasopressors, have no new serious conditions, require low ventilatory and PEEP settings, and have low FiO₂ requirements safely met with face mask or nasal cannula 1
• Consider extubation if spontaneous breathing trial is successful 1

Critical Pitfalls to Avoid

• Never allow tidal volumes to exceed 8 mL/kg predicted body weight when oxygenation is difficult—this causes ventilator-induced lung injury and increases mortality 2
• Do not delay prone positioning in severe ARDS while attempting less effective measures 2
• Avoid applying high PEEP indiscriminately without monitoring for adverse hemodynamic effects or reduced compliance 2
• Do not target normal-range oxygen levels (PaO₂ >90 mmHg or SpO₂ >97%), as this requires excessive FiO₂/PEEP and increases oxygen toxicity risk 2
• Do not extend neuromuscular blockade beyond 48 hours due to risk of ICU-acquired weakness, especially with concurrent corticosteroids 2